Article Text

Download PDFPDF

2022-RA-1309-ESGO Analysis of the prognostic value of systemic inflammation markers obtained from the complete blood count in patients treated for advanced ovarian carcinoma at the CUN in the period 2000–2015
Free
  1. Jaime Espinós Jiménez1,
  2. José Manuel Aramendía Beitia2,
  3. Matías Jurado Chacón3,
  4. José Ángel Mínguez Milio3,
  5. Luis Chiva4,
  6. Marta Santisteban Eslava2,
  7. Julia Villamayor1,
  8. Luisa Sánchez Lorenzo1,
  9. Daniel Vazquez4,
  10. Teresa Castellanos4,
  11. Félix Boria4,
  12. Enrique Chacón3,
  13. Andrés Alcázar5,
  14. Lidia Sancho6,
  15. Teresa Iscar7,
  16. Antonio González Martín1 and
  17. Juan Luis Alcázar Zambrano3
  1. 1Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain
  2. 2Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain
  3. 3Gynaecology and Obstetrics, Clínica Universidad de Navarra, Pamplona, Spain
  4. 4Gynaecology and Obstetrics, Clínica Universidad de Navarra, Madrid, Spain
  5. 5Radiology, Clínica Universidad de Navarra, Madrid, Spain
  6. 6Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain
  7. 7Pathological Anatomy, Clínica Universidad de Navarra, Madrid, Spain

Abstract

Introduction/Background Markers of systemic inflammation have been described as prognostic factors in epithelial ovarian cancer (EOC). We aimed to retrospectively explore these new markers in our patient population and define its relationship with prognosis.

Methodology Medical records of patients with newly diagnosed FIGO stage III – IV EOC between 2000 and 2015 were reviewed. We examined the red cell distribution width (RDW), mean platelet volume (MPV), neutrophil to lymphocyte (NLR), monocyte to lymphocyte (MLR), and platelet to lymphocyte (PLR) ratios at diagnosis.

Results 77 patients were analyzed. Mean age 58.3 years. FIGO IIIC 56%, serous 87% (80% high grade). 69% had primary surgery, 47% optimal citorreduction. Relevant values at diagnosis: median RDW 13.7 (IQR 12.8 – 14.8), median MPV 8.6 fl (IQR 8.1 – 9.5), median NLR 3.4 (IQR 2.3 – 4–5), median MLR 0.3 (IQR 0.25 – 0.45), median PLR 217.5 (IQR 151.5 – 309.6). Survival analysis: Median PFS 21.8 months, CI95% 18.8 – 77.5. Median OS 74.4 months (CI95% 51.6 – 123.6). Multivariate Cox OS analysis: MLR≥0.245 was a risk factor for OS, HR 7.04, p=0.059 Univariate Cox PFS analysis: MLR at diagnosis >0.32 predicted worse PFS, 19.2 vs 31.7 months, p<0.001, HR 3.49. PLR at diagnosis >289.1 predicted worse PFS, 19.2 vs 24.8 months, p=0.01, HR 2. On multivariate PFS analysis none of the variables retained its significance.

Abstract 2022-RA-1309-ESGO Figure 1

Conclusion In our series, higher MLR at diagnosis predicted worse outcomes in FIGO III – IV patients.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.